| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.772 | 0.002 | 0.772 | Dopamine uptake inhibitor | 0.59 0.003 DBMET00335 0.057 0.041 DBMET02918 | ||
| 0.664 | 0.003 | 0.664 | 5 Hydroxytryptamine uptake inhibitor | 0.597 0.004 DBMET00335 0.115 0.022 DBMET02918 | ||
| 0.664 | 0.017 | 0.664 | Analgesic | 0.513 0.045 DBMET00335 0.458 0.062 DBMET02918 | ||
| 0.56 | 0.003 | 0.56 | Adrenaline uptake inhibitor | 0.514 0.003 DBMET00335 0.164 0.008 DBMET02918 | ||
| 0.532 | 0.01 | 0.532 | Anticonvulsant | 0.525 0.01 DBMET00335 | ||
| 0.503 | 0.01 | 0.503 | Psychostimulant | 0.39 0.024 DBMET00335 0.212 0.074 DBMET02918 | ||
| 0.487 | 0.04 | 0.487 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.35 0.151 DBMET00335 | ||
| 0.447 | 0.004 | 0.447 | Alpha 2b adrenoreceptor antagonist | 0.227 0.018 DBMET00335 | ||
| 0.446 | 0.005 | 0.446 | Antipruritic | 0.256 0.023 DBMET00335 0.134 0.115 DBMET02918 | ||
| 0.433 | 0.003 | 0.433 | Dopamine transporter inhibitor | 0.397 0.003 DBMET00335 0.133 0.007 DBMET02918 | ||
| 0.428 | 0.037 | 0.428 | Immunomodulator | 0.374 0.052 DBMET00335 0.372 0.053 DBMET02918 | ||
| 0.434 | 0.048 | 0.434 | Toll-Like receptor 7 agonist | 0.226 0.171 DBMET02918 | ||
| 0.434 | 0.048 | 0.434 | Toll-Like receptor agonist | 0.241 0.157 DBMET02918 | ||
| 0.424 | 0.041 | 0.639 | 5 Hydroxytryptamine release stimulant | 0.639 0.011 DBMET00335 | DBMET00335 | |
| 0.388 | 0.029 | 0.508 | Potassium channel (Voltage-sensitive) blocker | 0.508 0.014 DBMET00335 | DBMET00335 | |
| 0.399 | 0.059 | 0.399 | MAP kinase kinase 6 inhibitor | |||
| 0.325 | 0.005 | 0.337 | NMDA receptor antagonist | 0.337 0.005 DBMET00335 | DBMET00335 | |
| 0.335 | 0.015 | 0.364 | Lipocortins synthesis antagonist | 0.364 0.012 DBMET00335 0.288 0.023 DBMET02918 | DBMET00335 | |
| 0.311 | 0.003 | 0.311 | NMDA receptor subunit 3B antagonist | 0.192 0.005 DBMET00335 | ||
| 0.288 | 0.007 | 0.288 | Alpha 2a adrenoreceptor antagonist | 0.171 0.018 DBMET00335 | ||
| 0.322 | 0.044 | 0.462 | HERG channel blocker | 0.462 0.019 DBMET00335 | DBMET00335 | |
| 0.303 | 0.028 | 0.303 | 5 Hydroxytryptamine 1E antagonist | 0.275 0.05 DBMET00335 | ||
| 0.303 | 0.043 | 0.349 | 5 Hydroxytryptamine uptake stimulant | 0.349 0.026 DBMET00335 | DBMET00335 | |
| 0.267 | 0.007 | 0.267 | Dopamine D1 antagonist | 0.2 0.01 DBMET00335 | ||
| 0.272 | 0.013 | 0.272 | Dopamine antagonist | 0.15 0.026 DBMET00335 | ||
| 0.272 | 0.016 | 0.272 | MAP kinase kinase 3 inhibitor | |||
| 0.264 | 0.01 | 0.264 | Alpha 2 adrenoreceptor antagonist | 0.141 0.03 DBMET00335 | ||
| 0.258 | 0.009 | 0.258 | Alpha 2c adrenoreceptor antagonist | 0.152 0.031 DBMET00335 | ||
| 0.259 | 0.012 | 0.259 | Dopamine D2 antagonist | 0.14 0.024 DBMET00335 | ||
| 0.263 | 0.02 | 0.263 | 5 Hydroxytryptamine 2 antagonist | 0.145 0.046 DBMET00335 | ||
| 0.253 | 0.015 | 0.253 | 5 Hydroxytryptamine 2A antagonist | 0.121 0.037 DBMET00335 | ||
| 0.24 | 0.004 | 0.24 | NMDA receptor subunit 3A antagonist | 0.141 0.005 DBMET00335 | ||
| 0.241 | 0.006 | 0.241 | Alpha adrenoreceptor agonist | 0.15 0.016 DBMET00335 | ||
| 0.252 | 0.025 | 0.252 | 5 Hydroxytryptamine antagonist | 0.129 0.06 DBMET00335 | ||
| 0.246 | 0.019 | 0.246 | 5 Hydroxytryptamine 2B antagonist | 0.156 0.038 DBMET00335 | ||
| 0.292 | 0.073 | 0.292 | Spasmolytic | 0.26 0.087 DBMET00335 0.229 0.101 DBMET02918 | ||
| 0.272 | 0.056 | 0.324 | Potassium channel blocker | 0.324 0.039 DBMET00335 | DBMET00335 | |
| 0.319 | 0.104 | 0.326 | Antiobesity | 0.229 0.177 DBMET00335 0.326 0.1 DBMET02918 | DBMET02918 | |
| 0.234 | 0.02 | 0.234 | Calcium channel blocker | 0.191 0.034 DBMET00335 | ||
| 0.302 | 0.096 | 0.302 | Vasodilator, peripheral | 0.217 0.157 DBMET00335 0.224 0.15 DBMET02918 | ||
| 0.334 | 0.129 | 0.357 | 5 Hydroxytryptamine release inhibitor | 0.357 0.109 DBMET00335 0.28 0.188 DBMET02918 | DBMET00335 | |
| 0.259 | 0.069 | 0.259 | Gastrin inhibitor | 0.197 0.154 DBMET00335 0.208 0.136 DBMET02918 | ||
| 0.253 | 0.07 | 0.428 | Antiamyloidogenic | 0.428 0.025 DBMET02918 | DBMET02918 | |
| 0.176 | 0.004 | 0.176 | 5 Hydroxytryptamine 2 agonist | 0.123 0.006 DBMET00335 | ||
| 0.175 | 0.004 | 0.175 | Lysine-specific demethylase 1A inhibitor | 0.141 0.004 DBMET00335 | ||
| 0.202 | 0.031 | 0.202 | MAP kinase kinase 5 inhibitor | 0.154 0.138 DBMET00335 | ||
| 0.186 | 0.016 | 0.186 | Pregnane X receptor agonist | 0.175 0.022 DBMET00335 | ||
| 0.228 | 0.068 | 0.336 | Peptidyltransferase inhibitor | 0.336 0.015 DBMET02918 | DBMET02918 | |
| 0.239 | 0.08 | 0.239 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.168 | 0.01 | 0.168 | Beta tubulin antagonist | 0.144 0.013 DBMET00335 | ||
| 0.193 | 0.039 | 0.193 | Tubulin antagonist | 0.151 0.057 DBMET00335 | ||
| 0.189 | 0.036 | 0.289 | Topoisomerase II inhibitor | 0.173 0.04 DBMET00335 0.289 0.019 DBMET02918 | DBMET02918 | |
| 0.215 | 0.063 | 0.244 | Neurotrophic factor enhancer | 0.244 0.042 DBMET00335 | DBMET00335 | |
| 0.164 | 0.013 | 0.164 | Dopamine agonist | 0.123 0.019 DBMET00335 | ||
| 0.163 | 0.014 | 0.163 | Dopamine D3 antagonist | 0.099 0.025 DBMET00335 | ||
| 0.167 | 0.018 | 0.42 | Sphingosine 1-phosphate receptor 2 agonist | 0.42 0.003 DBMET00335 | DBMET00335 | |
| 0.179 | 0.031 | 0.179 | Neuropeptide Y1 antagonist | 0.161 0.05 DBMET00335 | ||
| 0.152 | 0.006 | 0.152 | Alpha 2 adrenoreceptor agonist | 0.075 0.027 DBMET00335 | ||
| 0.162 | 0.016 | 0.162 | Potassium channel activator | 0.101 0.047 DBMET00335 | ||
| 0.144 | 0.005 | 0.181 | 5 Hydroxytryptamine 2A agonist | 0.181 0.004 DBMET00335 | DBMET00335 | |
| 0.306 | 0.168 | 0.51 | Apoptosis agonist | 0.51 0.071 DBMET02918 | DBMET02918 | |
| 0.16 | 0.024 | 0.16 | 5 Hydroxytryptamine 2C antagonist | 0.089 0.054 DBMET00335 | ||
| 0.254 | 0.125 | 0.419 | Transcription factor NF kappa B inhibitor | 0.198 0.171 DBMET00335 0.419 0.059 DBMET02918 | DBMET02918 | |
| 0.137 | 0.01 | 0.137 | Alpha 1 adrenoreceptor agonist | 0.077 0.024 DBMET00335 | ||
| 0.18 | 0.054 | 0.397 | Diuretic | 0.397 0.013 DBMET00335 0.322 0.019 DBMET02918 | DBMET00335 | |
| 0.177 | 0.052 | 0.264 | NOS3 expression enhancer | 0.19 0.045 DBMET00335 0.264 0.024 DBMET02918 | DBMET02918 | |
| 0.159 | 0.035 | 0.159 | Alpha adrenoreceptor antagonist | 0.103 0.055 DBMET00335 | ||
| 0.145 | 0.023 | 0.145 | Alpha 1b adrenoreceptor antagonist | 0.086 0.042 DBMET00335 | ||
| 0.176 | 0.055 | 0.176 | Cyclin-dependent kinase 8 inhibitor | 0.143 0.086 DBMET00335 | ||
| 0.123 | 0.005 | 0.123 | Potassium channel intermediate-conductance Ca-activated blocker | 0.116 0.006 DBMET00335 | ||
| 0.136 | 0.018 | 0.136 | Glutamate (mGluR7) agonist | 0.116 0.034 DBMET00335 | ||
| 0.151 | 0.033 | 0.151 | Calcium channel (voltage-sensitive) blocker | 0.107 0.074 DBMET00335 | ||
| 0.135 | 0.019 | 0.135 | Dopamine D4 antagonist | 0.073 0.035 DBMET00335 | ||
| 0.118 | 0.005 | 0.118 | Nicotinic alpha3beta2 receptor antagonist | 0.086 0.011 DBMET00335 | ||
| 0.121 | 0.008 | 0.121 | Glycine transporter inhibitor | 0.086 0.015 DBMET00335 | ||
| 0.117 | 0.005 | 0.117 | Bradykinin B1 receptor antagonist | |||
| 0.119 | 0.008 | 0.119 | Dopamine D5 antagonist | 0.119 0.008 DBMET00335 | ||
| 0.115 | 0.004 | 0.115 | Histamine H4 receptor antagonist | 0.09 0.006 DBMET00335 | ||
| 0.169 | 0.061 | 0.169 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.252 | 0.145 | 0.281 | Calcium channel activator | 0.281 0.112 DBMET00335 | DBMET00335 | |
| 0.144 | 0.038 | 0.144 | Interleukin 8 antagonist | 0.105 0.086 DBMET00335 | ||
| 0.171 | 0.066 | 0.171 | Death-associated protein kinase 2 inhibitor | |||
| 0.127 | 0.022 | 0.127 | NMDA 2 receptor antagonist | 0.1 0.032 DBMET00335 | ||
| 0.162 | 0.058 | 0.162 | CF transmembrane conductance regulator agonist | 0.147 0.082 DBMET00335 0.132 0.113 DBMET02918 | ||
| 0.132 | 0.031 | 0.132 | Prolactin inhibitor | 0.12 0.038 DBMET00335 | ||
| 0.136 | 0.037 | 0.216 | Nav1.5 sodium channel blocker | 0.216 0.01 DBMET00335 | DBMET00335 | |
| 0.117 | 0.02 | 0.127 | Glycine receptor antagonist | 0.117 0.02 DBMET00335 0.127 0.015 DBMET02918 | DBMET02918 | |
| 0.117 | 0.019 | 0.121 | Nicotinic alpha4beta2 receptor antagonist | 0.121 0.017 DBMET00335 | DBMET00335 | |
| 0.114 | 0.018 | 0.114 | Calcium channel L-type blocker | 0.084 0.035 DBMET00335 | ||
| 0.135 | 0.04 | 0.206 | GABA C receptor antagonist | 0.206 0.012 DBMET00335 | DBMET00335 | |
| 0.108 | 0.013 | 0.119 | NMDA 2C receptor antagonist | 0.119 0.011 DBMET00335 | DBMET00335 | |
| 0.16 | 0.066 | 0.16 | Acetylcholine M1 receptor antagonist | 0.131 0.095 DBMET00335 | ||
| 0.099 | 0.006 | 0.099 | Bradykinin antagonist | |||
| 0.104 | 0.012 | 0.104 | CC chemokine 2 receptor antagonist | 0.079 0.019 DBMET00335 | ||
| 0.203 | 0.115 | 0.203 | Cardiotonic | |||
| 0.121 | 0.037 | 0.121 | Alpha 1 adrenoreceptor antagonist | 0.086 0.049 DBMET00335 | ||
| 0.112 | 0.028 | 0.16 | Glutamate release inhibitor | 0.16 0.008 DBMET00335 0.122 0.02 DBMET02918 | DBMET00335 | |
| 0.088 | 0.006 | 0.088 | Potassium channel (Inward rectifier) activator | 0.059 0.02 DBMET00335 | ||
| 0.086 | 0.005 | 0.086 | Potassium channel (ATP-sensitive) activator | 0.057 0.02 DBMET00335 | ||
| 0.121 | 0.042 | 0.121 | Antihistaminic | |||
| 0.133 | 0.055 | 0.148 | Cholesterol synthesis inhibitor | 0.148 0.045 DBMET00335 0.131 0.056 DBMET02918 | DBMET00335 | |
| 0.147 | 0.069 | 0.153 | Adenylate cyclase stimulant | 0.153 0.058 DBMET00335 | DBMET00335 | |
| 0.081 | 0.005 | 0.081 | GABA uptake inhibitor | 0.06 0.01 DBMET00335 | ||
| 0.1 | 0.025 | 0.1 | Epoxide hydrolase inhibitor | |||
| 0.139 | 0.065 | 0.139 | MAO inhibitor | 0.138 0.066 DBMET00335 | ||
| 0.113 | 0.041 | 0.113 | Histamine antagonist | |||
| 0.077 | 0.005 | 0.096 | 5 Hydroxytryptamine 2B agonist | 0.096 0.004 DBMET00335 | DBMET00335 | |
| 0.129 | 0.058 | 0.129 | Sphingosine 1-phosphate receptor 4 antagonist | 0.106 0.103 DBMET00335 | ||
| 0.107 | 0.036 | 0.216 | Topoisomerase II alpha inhibitor | 0.122 0.029 DBMET00335 0.216 0.013 DBMET02918 | DBMET02918 | |
| 0.235 | 0.169 | 0.339 | GABA C receptor rho-3 antagonist | 0.339 0.092 DBMET00335 | DBMET00335 | |
| 0.178 | 0.112 | 0.178 | 5 Hydroxytryptamine 3E antagonist | 0.172 0.129 DBMET00335 | ||
| 0.12 | 0.056 | 0.161 | 5 Hydroxytryptamine 3A agonist | 0.161 0.03 DBMET00335 | DBMET00335 | |
| 0.083 | 0.019 | 0.083 | NMDA 2A receptor antagonist | 0.045 0.042 DBMET00335 | ||
| 0.088 | 0.027 | 0.088 | Alpha 1d adrenoreceptor antagonist | 0.065 0.037 DBMET00335 | ||
| 0.11 | 0.05 | 0.157 | GABA C receptor rho-1 antagonist | 0.157 0.018 DBMET00335 | DBMET00335 | |
| 0.08 | 0.02 | 0.08 | Sigma receptor antagonist | 0.062 0.027 DBMET00335 | ||
| 0.109 | 0.05 | 0.109 | Antiadrenergic | 0.083 0.068 DBMET00335 | ||
| 0.095 | 0.038 | 0.095 | Alpha 1a adrenoreceptor antagonist | 0.086 0.042 DBMET00335 | ||
| 0.067 | 0.009 | 0.145 | Dopamine D5 agonist | 0.145 0.003 DBMET00335 | DBMET00335 | |
| 0.073 | 0.016 | 0.073 | Dopamine D2 agonist | |||
| 0.09 | 0.034 | 0.129 | Lipase inhibitor | 0.129 0.015 DBMET02918 | DBMET02918 | |
| 0.079 | 0.025 | 0.079 | Acetylcholine M5 receptor antagonist | 0.06 0.043 DBMET00335 | ||
| 0.124 | 0.07 | 0.14 | Glutamate receptor antagonist | 0.14 0.058 DBMET00335 | DBMET00335 | |
| 0.088 | 0.034 | 0.088 | Cannabinoid receptor antagonist | 0.085 0.037 DBMET00335 | ||
| 0.062 | 0.008 | 0.062 | Alpha 1L adrenoreceptor agonist | 0.061 0.008 DBMET00335 | ||
| 0.069 | 0.015 | 0.071 | 5 Hydroxytryptamine 2C agonist | 0.071 0.014 DBMET00335 | DBMET00335 | |
| 0.104 | 0.051 | 0.104 | Adrenaline antagonist | 0.078 0.07 DBMET00335 | ||
| 0.077 | 0.025 | 0.077 | 5 Hydroxytryptamine 5A antagonist | 0.067 0.035 DBMET00335 | ||
| 0.07 | 0.019 | 0.07 | Histamine agonist | 0.063 0.024 DBMET00335 | ||
| 0.077 | 0.026 | 0.077 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.139 | 0.088 | 0.139 | MAP kinase kinase 4 inhibitor | |||
| 0.089 | 0.038 | 0.089 | Acetylcholine M4 receptor antagonist | |||
| 0.059 | 0.009 | 0.069 | Histamine H1 receptor agonist | 0.069 0.005 DBMET00335 | DBMET00335 | |
| 0.093 | 0.045 | 0.093 | Neuropeptide Y antagonist | |||
| 0.092 | 0.045 | 0.094 | Hematopoietic | 0.094 0.043 DBMET00335 | DBMET00335 | |
| 0.071 | 0.025 | 0.071 | 5 Hydroxytryptamine 5 antagonist | 0.06 0.036 DBMET00335 | ||
| 0.069 | 0.024 | 0.069 | Cannabinoid CB2 receptor antagonist | 0.069 0.024 DBMET00335 | ||
| 0.09 | 0.048 | 0.09 | Histamine H1 receptor antagonist | |||
| 0.092 | 0.051 | 0.092 | Bromodomain-containing protein 2 inhibitor | |||
| 0.045 | 0.004 | 0.045 | Hedgehog signaling activator | 0.036 0.006 DBMET00335 | ||
| 0.189 | 0.149 | 0.189 | Transcription factor STAT3 inhibitor | |||
| 0.147 | 0.107 | 0.207 | ATPase inhibitor | 0.147 0.107 DBMET00335 0.207 0.032 DBMET02918 | DBMET02918 | |
| 0.113 | 0.073 | 0.113 | Adenylate cyclase inhibitor | 0.112 0.074 DBMET00335 | ||
| 0.067 | 0.028 | 0.067 | Prolactin release inhibitor | 0.064 0.036 DBMET00335 | ||
| 0.065 | 0.027 | 0.108 | Alpha tubulin antagonist | 0.108 0.014 DBMET00335 | DBMET00335 | |
| 0.071 | 0.034 | 0.077 | Cannabinoid CB1 receptor antagonist | 0.077 0.029 DBMET00335 | DBMET00335 | |
| 0.05 | 0.015 | 0.05 | Glycine transporter 1 inhibitor | 0.036 0.023 DBMET00335 | ||
| 0.085 | 0.051 | 0.085 | Opioid kappa receptor antagonist | |||
| 0.048 | 0.015 | 0.06 | p53 inhibitor | 0.06 0.009 DBMET00335 | DBMET00335 | |
| 0.066 | 0.032 | 0.066 | Potassium channel Kv1.5 blocker | 0.053 0.044 DBMET00335 | ||
| 0.056 | 0.023 | 0.056 | CC chemokine receptor 2B antagonist | 0.056 0.023 DBMET00335 | ||
| 0.078 | 0.044 | 0.078 | Vanilloid 4 agonist | 0.073 0.055 DBMET00335 | ||
| 0.119 | 0.086 | 0.216 | Sodium channel blocker | 0.216 0.027 DBMET00335 | DBMET00335 | |
| 0.048 | 0.015 | 0.061 | Antibiotic Aminoglycoside-like | 0.035 0.027 DBMET00335 0.061 0.008 DBMET02918 | DBMET02918 | |
| 0.146 | 0.114 | 0.193 | Phospholipase C inhibitor | 0.193 0.049 DBMET00335 0.14 0.127 DBMET02918 | DBMET00335 | |
| 0.051 | 0.02 | 0.051 | Parathyroid hormone antagonist | 0.05 0.022 DBMET00335 | ||
| 0.108 | 0.077 | 0.162 | Microtubule formation inhibitor | 0.162 0.032 DBMET02918 | DBMET02918 | |
| 0.068 | 0.038 | 0.068 | 5 Hydroxytryptamine 7 antagonist | |||
| 0.05 | 0.021 | 0.05 | Baculoviral IAP repeat-containing protein inhibitor | |||
| 0.06 | 0.031 | 0.06 | 5 Hydroxytryptamine 7 agonist | |||
| 0.048 | 0.019 | 0.048 | Progesterone antagonist | 0.036 0.024 DBMET00335 | ||
| 0.053 | 0.024 | 0.053 | CC chemokine 4 receptor antagonist | |||
| 0.052 | 0.024 | 0.052 | Secretase gamma inhibitor | 0.039 0.032 DBMET00335 | ||
| 0.091 | 0.065 | 0.098 | MAO B inhibitor | 0.098 0.061 DBMET00335 | DBMET00335 | |
| 0.132 | 0.107 | 0.155 | Ca2+-transporting ATPase inhibitor | 0.155 0.032 DBMET00335 0.131 0.112 DBMET02918 | DBMET00335 | |
| 0.08 | 0.054 | 0.08 | Acetylcholine nicotinic antagonist | |||
| 0.27 | 0.245 | 0.68 | Antiinflammatory | 0.68 0.035 DBMET02918 | DBMET02918 | |
| 0.029 | 0.005 | 0.029 | NMDA receptor phencyclidine site antagonist | 0.021 0.007 DBMET00335 | ||
| 0.128 | 0.104 | 0.128 | Sigma receptor agonist | |||
| 0.12 | 0.096 | 0.195 | Nav1.6 sodium channel blocker | 0.195 0.021 DBMET00335 | DBMET00335 | |
| 0.106 | 0.083 | 0.106 | Histone deacetylase class III inhibitor | |||
| 0.067 | 0.045 | 0.105 | Glutamate (mGluR6) antagonist | 0.105 0.009 DBMET00335 | DBMET00335 | |
| 0.047 | 0.026 | 0.047 | Opioid kappa receptor agonist | |||
| 0.059 | 0.037 | 0.059 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.204 | 0.183 | 0.237 | Sodium/bile acid cotransporter inhibitor | 0.237 0.142 DBMET02918 | DBMET02918 | |
| 0.043 | 0.022 | 0.043 | Alpha 1d adrenoreceptor agonist | 0.038 0.028 DBMET00335 | ||
| 0.068 | 0.048 | 0.068 | 5 Hydroxytryptamine agonist | |||
| 0.047 | 0.027 | 0.047 | Nicotinic receptor alpha3 subunit antagonist | 0.046 0.028 DBMET00335 | ||
| 0.065 | 0.045 | 0.065 | Aryl hydrocarbon receptor antagonist | |||
| 0.067 | 0.047 | 0.077 | MDM2 inhibitor | 0.077 0.024 DBMET00335 | DBMET00335 | |
| 0.051 | 0.031 | 0.055 | Topoisomerase II beta inhibitor | 0.055 0.027 DBMET00335 | DBMET00335 | |
| 0.082 | 0.063 | 0.082 | Acetylcholine agonist | |||
| 0.062 | 0.044 | 0.062 | I kappa B kinase 2 inhibitor | 0.056 0.054 DBMET00335 | ||
| 0.07 | 0.053 | 0.07 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.111 | 0.095 | 0.18 | Sodium channel (voltage-gated) blocker | 0.18 0.037 DBMET00335 | DBMET00335 | |
| 0.104 | 0.088 | 0.104 | Calcium channel N-type blocker | |||
| 0.058 | 0.042 | 0.058 | Cyclin H inhibitor | |||
| 0.084 | 0.069 | 0.084 | Aminoacyl-tRNA synthetase inhibitor | |||
| 0.09 | 0.075 | 0.09 | Chemokine receptor antagonist | |||
| 0.068 | 0.053 | 0.068 | CXC chemokine receptor antagonist | |||
| 0.058 | 0.044 | 0.058 | Potassium channel (Ca-activated) blocker | 0.057 0.047 DBMET00335 | ||
| 0.062 | 0.049 | 0.062 | Beta 3 adrenoreceptor antagonist | |||
| 0.034 | 0.022 | 0.036 | Glucocorticoid antagonist | 0.036 0.021 DBMET00335 | DBMET00335 | |
| 0.021 | 0.009 | 0.021 | Alpha 2a adrenoreceptor agonist | 0.019 0.01 DBMET00335 | ||
| 0.032 | 0.02 | 0.032 | Endothelial nitric-oxide synthase inhibitor | |||
| 0.033 | 0.022 | 0.033 | Protein kinase (CK2) beta inhibitor | |||
| 0.021 | 0.01 | 0.021 | Histamine H4 receptor agonist | 0.017 0.014 DBMET00335 | ||
| 0.102 | 0.092 | 0.102 | Cholinergic antagonist | |||
| 0.049 | 0.039 | 0.049 | Alpha 1b adrenoreceptor agonist | 0.049 0.038 DBMET00335 | ||
| 0.083 | 0.074 | 0.162 | HIV-1 integrase (Overall Integration) inhibitor | 0.162 0.021 DBMET00335 | DBMET00335 | |
| 0.051 | 0.042 | 0.051 | Acetylcholine muscarinic agonist | |||
| 0.056 | 0.047 | 0.056 | Cannabinoid CB1 receptor agonist | |||
| 0.084 | 0.075 | 0.084 | Protein kinase C mu inhibitor | |||
| 0.049 | 0.041 | 0.049 | Phosphodiesterase 7A inhibitor | |||
| 0.027 | 0.019 | 0.027 | Glucosylceramidase stimulant | |||
| 0.019 | 0.012 | 0.023 | Cyclin T1 inhibitor | 0.023 0.008 DBMET00335 | DBMET00335 | |
| 0.024 | 0.017 | 0.044 | Protein 30S ribosomal subunit inhibitor | 0.044 0.009 DBMET02918 | DBMET02918 | |
| 0.075 | 0.068 | 0.075 | I kappa B kinase inhibitor | |||
| 0.1 | 0.093 | 0.1 | Acetylcholine antagonist | |||
| 0.069 | 0.063 | 0.074 | Analgesic, opioid | 0.074 0.055 DBMET00335 | DBMET00335 | |
| 0.022 | 0.016 | 0.026 | Alpha 1a adrenoreceptor agonist | 0.026 0.012 DBMET00335 | DBMET00335 | |
| 0.016 | 0.01 | 0.016 | Antibiotic Tetracycline-like | |||
| 0.185 | 0.179 | 0.557 | Cholesterol antagonist | 0.212 0.155 DBMET00335 0.557 0.024 DBMET02918 | DBMET02918 | |
| 0.172 | 0.166 | 0.273 | DNA synthesis inhibitor | 0.201 0.121 DBMET00335 0.273 0.054 DBMET02918 | DBMET02918 | |
| 0.066 | 0.06 | 0.066 | Histone deacetylase SIRT2 inhibitor | |||
| 0.023 | 0.018 | 0.023 | Epoxide hydrolase 2 inhibitor | |||
| 0.046 | 0.041 | 0.046 | Dopamine D4 agonist | |||
| 0.08 | 0.076 | 0.102 | Potassium channel (Ca-activated) activator | 0.102 0.053 DBMET00335 | DBMET00335 | |
| 0.017 | 0.013 | 0.022 | Sodium/hydrogen exchanger inhibitor | 0.022 0.007 DBMET00335 | DBMET00335 | |
| 0.038 | 0.034 | 0.053 | Phenylethanolamine N methyltransferase inhibitor | 0.053 0.012 DBMET00335 | DBMET00335 | |
| 0.025 | 0.021 | 0.025 | Integrin alpha2beta1 antagonist | |||
| 0.042 | 0.038 | 0.045 | Adenylate cyclase 1 inhibitor | 0.045 0.034 DBMET00335 | DBMET00335 | |
| 0.036 | 0.032 | 0.036 | Dopamine D3 agonist | |||
| 0.02 | 0.016 | 0.02 | Baculoviral IAP repeat-containing protein 3 inhibitor | |||
| 0.041 | 0.038 | 0.041 | Glycine transporter 2 inhibitor | |||
| 0.165 | 0.162 | 0.192 | RNA-directed DNA polymerase inhibitor | 0.192 0.112 DBMET00335 | DBMET00335 | |
| 0.056 | 0.054 | 0.056 | Transcription factor AP-1 inhibitor | |||
| 0.017 | 0.016 | 0.021 | Complement factor D inhibitor | 0.021 0.008 DBMET00335 | DBMET00335 | |
| 0.052 | 0.051 | 0.072 | Botulinum neurotoxin type A inhibitor | 0.072 0.023 DBMET00335 | DBMET00335 | |
| 0.09 | 0.09 | 0.131 | Cystathionine beta-synthase inhibitor | 0.131 0.05 DBMET00335 | DBMET00335 | |
| 0.122 | 0.123 | 0.154 | Arachidonic acid antagonist | 0.154 0.084 DBMET00335 | DBMET00335 | |
| 0.042 | 0.044 | 0.053 | Aldosterone antagonist | 0.053 0.025 DBMET00335 | DBMET00335 | |
| 0.017 | 0.019 | 0.018 | Alpha 2b adrenoreceptor agonist | 0.018 0.014 DBMET00335 | DBMET00335 | |
| 0.022 | 0.026 | 0.032 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.032 0.015 DBMET00335 | DBMET00335 | |
| 0.014 | 0.017 | 0.017 | Progesterone agonist | 0.017 0.013 DBMET00335 | DBMET00335 | |
| 0.026 | 0.029 | 0.028 | Potassium channel small-conductance Ca-activated activator | 0.028 0.026 DBMET00335 | DBMET00335 | |
| 0.084 | 0.089 | 0.221 | GABA C receptor agonist | 0.221 0.017 DBMET00335 | DBMET00335 | |
| 0.051 | 0.057 | 0.059 | NMDA receptor glycine site agonist | 0.059 0.047 DBMET00335 | DBMET00335 | |
| 0.06 | 0.066 | 0.073 | Glutamate (mGluR7) antagonist | 0.073 0.037 DBMET00335 | DBMET00335 | |
| 0.022 | 0.029 | 0.027 | Calcium-sensing receptor agonist | 0.027 0.017 DBMET00335 | DBMET00335 | |
| 0.119 | 0.125 | 0.14 | CC chemokine 6 receptor antagonist | 0.14 0.041 DBMET02918 | DBMET02918 | |
| 0.051 | 0.059 | 0.056 | Pregnane X receptor antagonist | 0.056 0.042 DBMET00335 | DBMET00335 | |
| 0.034 | 0.044 | 0.131 | Phosphorylase inhibitor | 0.045 0.033 DBMET00335 0.131 0.009 DBMET02918 | DBMET02918 | |
| 0.018 | 0.028 | 0.025 | Dopamine D1 agonist | 0.025 0.013 DBMET00335 | DBMET00335 | |
| 0.028 | 0.038 | 0.06 | Factor XI inhibitor | 0.06 0.007 DBMET00335 | DBMET00335 | |
| 0.024 | 0.034 | 0.032 | Purinergic P2Y15 antagonist | 0.032 0.014 DBMET00335 | DBMET00335 | |
| 0.074 | 0.087 | 0.104 | MAO A inhibitor | 0.104 0.061 DBMET00335 | DBMET00335 | |
| 0.099 | 0.113 | 0.117 | Nav1.2 sodium channel blocker | 0.117 0.087 DBMET00335 | DBMET00335 | |
| 0.051 | 0.065 | 0.059 | NMDA receptor agonist | 0.059 0.048 DBMET00335 | DBMET00335 | |
| 0.183 | 0.198 | 0.242 | Caspase 3 stimulant | 0.2 0.169 DBMET00335 0.242 0.119 DBMET02918 | DBMET02918 | |
| 0.137 | 0.152 | 0.174 | Aldehyde oxidase inhibitor | 0.174 0.12 DBMET00335 | DBMET00335 | |
| 0.13 | 0.15 | 0.167 | P-glycoprotein inhibitor | 0.167 0.093 DBMET02918 | DBMET02918 | |
| 0.056 | 0.077 | 0.073 | Calcium channel P-type blocker | 0.073 0.023 DBMET00335 | DBMET00335 | |
| 0.107 | 0.128 | 0.152 | Cholinergic | 0.152 0.075 DBMET00335 | DBMET00335 | |
| 0.078 | 0.103 | 0.107 | Electrolyte absorption antagonist | 0.107 0.049 DBMET00335 | DBMET00335 | |
| 0.089 | 0.116 | 0.113 | Acetylcholine release stimulant | 0.113 0.06 DBMET00335 | DBMET00335 | |
| 0.026 | 0.055 | 0.049 | Glutamate (mGluR3) antagonist | 0.049 0.013 DBMET00335 | DBMET00335 | |
| 0.058 | 0.088 | 0.105 | GABA aminotransferase inhibitor | 0.105 0.024 DBMET00335 0.085 0.04 DBMET02918 | DBMET00335 | |
| 0.018 | 0.05 | 0.03 | Sodium/glucose cotransporter inhibitor | 0.03 0.011 DBMET02918 | DBMET02918 | |
| 0.063 | 0.096 | 0.082 | Myeloperoxidase inhibitor | 0.082 0.063 DBMET00335 | DBMET00335 | |
| 0.076 | 0.108 | 0.091 | Anabolic | 0.091 0.077 DBMET00335 | DBMET00335 | |
| 0.056 | 0.089 | 0.068 | Phospholipase D inhibitor | 0.068 0.058 DBMET00335 | DBMET00335 | |
| 0.07 | 0.104 | 0.098 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.098 0.056 DBMET00335 | DBMET00335 | |
| 0.139 | 0.174 | 0.156 | Cyclic AMP phosphodiesterase inhibitor | 0.156 0.143 DBMET02918 | DBMET02918 | |
| 0.048 | 0.084 | 0.064 | Nav1.7 sodium channel blocker | 0.064 0.052 DBMET00335 | DBMET00335 | |
| 0.028 | 0.064 | 0.039 | AMPA 4 receptor antagonist | 0.039 0.029 DBMET00335 | DBMET00335 | |
| 0.02 | 0.06 | 0.03 | Toll-Like receptor 4 agonist | 0.03 0.011 DBMET02918 | DBMET02918 | |
| 0.116 | 0.157 | 0.146 | Anesthetic general | 0.146 0.118 DBMET02918 | DBMET02918 | |
| 0.039 | 0.083 | 0.083 | Sphingosine kinase 2 inhibitor | 0.083 0.014 DBMET00335 | DBMET00335 | |
| 0.046 | 0.091 | 0.06 | Corticotropin releasing factor 2 receptor antagonist | 0.06 0.046 DBMET00335 | DBMET00335 | |
| 0.066 | 0.112 | 0.083 | Pim-3 kinase inhibitor | 0.083 0.071 DBMET00335 | DBMET00335 | |
| 0.069 | 0.118 | 0.101 | Lanosterol 14 alpha demethylase inhibitor | 0.101 0.054 DBMET00335 | DBMET00335 | |
| 0.071 | 0.12 | 0.1 | Nitric-oxide synthase inhibitor | 0.1 0.06 DBMET00335 | DBMET00335 | |
| 0.083 | 0.132 | 0.106 | Alpha-N-acetylglucosaminidase inhibitor | 0.106 0.093 DBMET02918 | DBMET02918 | |
| 0.009 | 0.059 | 0.021 | Dopamine autoreceptor agonist | 0.021 0.019 DBMET00335 | DBMET00335 | |
| 0.036 | 0.086 | 0.058 | Alpha-mannosidase inhibitor | 0.058 0.03 DBMET02918 | DBMET02918 | |
| 0.012 | 0.073 | 0.036 | Sodium/glucose cotransporter 2 inhibitor | 0.036 0.01 DBMET02918 | DBMET02918 | |
| 0.093 | 0.154 | 0.19 | Cell wall synthesis inhibitor | 0.19 0.034 DBMET02918 | DBMET02918 | |
| 0.026 | 0.091 | 0.039 | Sphingosine kinase 1 inhibitor | 0.039 0.033 DBMET00335 | DBMET00335 | |
| 0.037 | 0.102 | 0.076 | Sphingosine 1-phosphate receptor 4 agonist | 0.076 0.04 DBMET00335 | DBMET00335 | |
| 0.011 | 0.079 | 0.024 | Antibiotic Anthracycline-like | 0.024 0.006 DBMET02918 | DBMET02918 | |
| 0.051 | 0.12 | 0.09 | Glycine receptor agonist | 0.09 0.028 DBMET00335 | DBMET00335 | |
| 0.03 | 0.101 | 0.041 | Glutamate (mGluR group III) antagonist | 0.041 0.036 DBMET00335 | DBMET00335 | |
| 0.077 | 0.148 | 0.117 | Acetylcholinesterase inhibitor | 0.117 0.081 DBMET00335 | DBMET00335 | |
| 0.038 | 0.11 | 0.061 | Sphingosine kinase inhibitor | 0.061 0.037 DBMET00335 | DBMET00335 | |
| 0.04 | 0.113 | 0.075 | Na+ K+ transporting ATPase inhibitor | 0.075 0.055 DBMET02918 | DBMET02918 | |
| 0.131 | 0.205 | 0.264 | DNA damaging | 0.264 0.073 DBMET00335 | DBMET00335 | |
| 0.044 | 0.123 | 0.065 | Potassium channel large-conductance Ca-activated activator | 0.065 0.05 DBMET02918 | DBMET02918 | |
| 0.022 | 0.102 | 0.069 | Aromatase inhibitor | 0.069 0.034 DBMET00335 | DBMET00335 | |
| 0.053 | 0.134 | 0.233 | Topoisomerase I inhibitor | 0.1 0.07 DBMET00335 0.233 0.019 DBMET02918 | DBMET02918 | |
| 0.036 | 0.119 | 0.062 | Sphingosine 1-phosphate receptor 5 agonist | 0.062 0.023 DBMET00335 | DBMET00335 | |
| 0.155 | 0.24 | 0.19 | Tyrosine 3 hydroxylase inhibitor | 0.19 0.155 DBMET00335 | DBMET00335 | |
| 0.02 | 0.106 | 0.03 | Glutamate (mGluR3) agonist | 0.03 0.029 DBMET00335 | DBMET00335 | |
| 0.034 | 0.121 | 0.053 | Dipeptidyl peptidase inhibitor | 0.053 0.037 DBMET00335 | DBMET00335 | |
| 0.021 | 0.11 | 0.044 | Mannosidase inhibitor | 0.044 0.033 DBMET02918 | DBMET02918 | |
| 0.029 | 0.12 | 0.043 | Dipeptidyl peptidase IV inhibitor | 0.043 0.035 DBMET00335 | DBMET00335 | |
| 0.064 | 0.158 | 0.149 | Amylase inhibitor | 0.125 0.078 DBMET00335 0.149 0.064 DBMET02918 | DBMET02918 | |
| 0.111 | 0.208 | 0.143 | Succinate dehydrogenase inhibitor | 0.143 0.127 DBMET00335 | DBMET00335 | |
| 0.107 | 0.206 | 0.438 | Immunostimulant | 0.438 0.039 DBMET02918 | DBMET02918 | |
| 0.137 | 0.26 | 0.169 | Nitric-oxide synthase stimulant | 0.169 0.155 DBMET00335 | DBMET00335 | |
| 0.104 | 0.228 | 0.276 | Tumour necrosis factor alpha release inhibitor | 0.276 0.063 DBMET02918 | DBMET02918 | |
| 0.158 | 0.286 | 0.566 | Antibacterial | 0.566 0.025 DBMET02918 | DBMET02918 | |
| 0.04 | 0.171 | 0.061 | Lipocortins synthesis agonist | 0.061 0.034 DBMET02918 | DBMET02918 | |
| 0.137 | 0.275 | 0.472 | Immunosuppressant | 0.472 0.041 DBMET02918 | DBMET02918 | |
| 0.092 | 0.231 | 0.16 | Interferon gamma antagonist | 0.16 0.066 DBMET02918 | DBMET02918 | |
| 0.028 | 0.172 | 0.06 | Epithelial sodium channel blocker | 0.06 0.029 DBMET00335 | DBMET00335 | |
| 0.027 | 0.172 | 0.062 | Heparanase inhibitor | 0.062 0.019 DBMET02918 | DBMET02918 | |
| 0.052 | 0.207 | 0.135 | Alkylator | 0.135 0.055 DBMET02918 | DBMET02918 | |
| 0.044 | 0.202 | 0.095 | ATPase (Vacuolar H+) inhibitor | 0.095 0.046 DBMET02918 | DBMET02918 | |
| 0.059 | 0.222 | 0.16 | Cyclooxygenase 3 inhibitor | 0.16 0.04 DBMET02918 | DBMET02918 | |
| 0.051 | 0.214 | 0.152 | AMP-activated protein kinase stimulant | 0.152 0.027 DBMET02918 | DBMET02918 | |
| 0.044 | 0.212 | 0.095 | UDP-glucose 4-epimerase inhibitor | 0.095 0.066 DBMET02918 | DBMET02918 | |
| 0.079 | 0.249 | 0.178 | Interleukin agonist | 0.178 0.141 DBMET02918 | DBMET02918 | |
| 0.064 | 0.247 | 0.148 | Protein kinase stimulant | 0.148 0.069 DBMET02918 | DBMET02918 | |
| 0.075 | 0.263 | 0.336 | Hepatoprotectant | 0.336 0.021 DBMET02918 | DBMET02918 | |
| 0.047 | 0.242 | 0.154 | Lipid peroxidase inhibitor | 0.154 0.066 DBMET02918 | DBMET02918 | |
| 0.117 | 0.313 | 0.283 | Vasodilator, coronary | 0.283 0.102 DBMET02918 | DBMET02918 | |
| 0.069 | 0.281 | 0.316 | Nitric oxide antagonist | 0.316 0.037 DBMET02918 | DBMET02918 | |
| 0.109 | 0.326 | 0.486 | Antithrombotic | 0.486 0.031 DBMET02918 | DBMET02918 | |
| 0.041 | 0.262 | 0.099 | Beta glucuronidase inhibitor | 0.099 0.072 DBMET02918 | DBMET02918 | |
| 0.012 | 0.244 | 0.132 | Antineoplastic antibiotic | 0.132 0.035 DBMET02918 | DBMET02918 | |
| 0.042 | 0.274 | 0.082 | NADH dehydrogenase inhibitor | 0.082 0.071 DBMET02918 | DBMET02918 | |
| 0.097 | 0.33 | 0.186 | Hypoxia-inducible factor 1 alpha inhibitor | 0.186 0.171 DBMET00335 | DBMET00335 | |
| 0.013 | 0.26 | 0.073 | Plasminogen activator inhibitor | 0.073 0.03 DBMET00335 | DBMET00335 | |
| 0.026 | 0.275 | 0.083 | Pim-1 kinase inhibitor | 0.083 0.076 DBMET00335 | DBMET00335 | |
| 0.044 | 0.306 | 0.112 | Transcription factor NF kappa B stimulant | 0.112 0.029 DBMET02918 | DBMET02918 | |
| 0.026 | 0.29 | 0.09 | Expectorant | 0.09 0.082 DBMET02918 | DBMET02918 | |
| 0.014 | 0.303 | 0.086 | Protein 50S ribosomal subunit inhibitor | 0.086 0.017 DBMET02918 | DBMET02918 | |
| 0.011 | 0.326 | 0.053 | Microtubule stabilization | 0.053 0.024 DBMET02918 | DBMET02918 | |
| 0.056 | 0.376 | 0.143 | Hemostatic | 0.143 0.077 DBMET02918 | DBMET02918 | |
| 0.052 | 0.397 | 0.207 | Vasodilator | 0.207 0.1 DBMET02918 | DBMET02918 | |
| 0.017 | 0.377 | 0.059 | Glucose-6-phosphate translocase inhibitor | 0.059 0.025 DBMET02918 | DBMET02918 | |
| 0.034 | 0.401 | 0.161 | Anticoagulant | 0.161 0.071 DBMET02918 | DBMET02918 | |
| 0.098 | 0.487 | 0.399 | Interleukin 2 agonist | 0.399 0.028 DBMET02918 | DBMET02918 | |
| 0.093 | 0.495 | 0.624 | Cyclophilin D inhibitor | 0.624 0.023 DBMET02918 | DBMET02918 | |
| 0.038 | 0.463 | 0.248 | Platelet adhesion inhibitor | 0.248 0.05 DBMET02918 | DBMET02918 | |
| 0.03 | 0.473 | 0.343 | Hypolipemic | 0.343 0.037 DBMET02918 | DBMET02918 | |
| 0.017 | 0.467 | 0.055 | Factor IXa inhibitor | 0.055 0.031 DBMET02918 | DBMET02918 | |
| 0.018 | 0.475 | 0.076 | Cell adhesion molecule inhibitor | 0.076 0.059 DBMET02918 | DBMET02918 | |
| 0.028 | 0.497 | 0.142 | Toll-Like receptor 4 antagonist | 0.142 0.026 DBMET02918 | DBMET02918 | |
| 0.021 | 0.547 | 0.463 | Angiogenesis stimulant | 0.463 0.014 DBMET02918 | DBMET02918 | |
| 0.038 | 0.566 | 0.192 | Angiogenesis inhibitor | 0.192 0.179 DBMET02918 | DBMET02918 | |
| 0.023 | 0.565 | 0.136 | Cell adhesion inhibitor | 0.136 0.055 DBMET02918 | DBMET02918 | |
| 0.02 | 0.595 | 0.056 | Adenine nucleotide translocase inhibitor | 0.056 0.038 DBMET02918 | DBMET02918 | |
| 0.019 | 0.634 | 0.341 | Antioxidant | 0.341 0.049 DBMET02918 | DBMET02918 | |
| 0.031 | 0.697 | 0.332 | Hypoglycemic | 0.332 0.042 DBMET02918 | DBMET02918 | |
| 0.012 | 0.684 | 0.189 | Thrombolytic | 0.189 0.057 DBMET02918 | DBMET02918 | |
| 0.005 | 0.7 | 0.06 | Neuraminidase (influenza) inhibitor | 0.06 0.054 DBMET02918 | DBMET02918 | |
| 0.004 | 0.709 | 0.24 | Selectin antagonist | 0.24 0.009 DBMET02918 | DBMET02918 | |
| 0.038 | 0.743 | 0.327 | Apoptosis antagonist | 0.327 0.068 DBMET02918 | DBMET02918 | |
| 0.009 | 0.724 | 0.32 | Free radical scavenger | 0.32 0.046 DBMET02918 | DBMET02918 | |
| 0.011 | 0.792 | 0.174 | Insulin secretagoues | 0.174 0.053 DBMET02918 | DBMET02918 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |